IP Library › Granted Patent US 12,384,743
Granted Patent B2
US 12,384,743 · App. 18/066,000 · Granted Aug 12, 2025

Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

Inventor: Fionn Hurley (Baldoyle, IE)
Assignees: AXSOME MALTA LTD.; SK BIOPHARMACEUTICALS CO., LTD.
C07C271/12A61K45/06A61P3/04A61P25/24C07B2200/13C07C269/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,384,743
App. No.
18/066,000
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.

Claims (7)

1. Crystalline (R)-2-amino-3-phenylpropyl carbamate hydrochloride having an X-ray powder diffraction pattern as shown in FIG. 1 Form A.

2. A composition comprising the crystalline (R)-2-amino-3-phenylpropyl carbamate hydrochloride of claim 1 .

3. The composition of claim 1 , wherein the composition is a dosage form.

4. The composition of claim 3 , wherein the composition is an immediate release dosage form.

5. The composition of claim 4 , wherein the composition is a tablet or a capsule.

6. A method of treating narcolepsy, cataplexy, excessive daytime sleepiness, drug addiction, sexual dysfunction, fatigue, fibromyalgia, attention deficit/hyperactivity disorder, restless legs syndrome, depression, bipolar disorder, or obesity in a subject in need thereof, or promoting smoking cessation in a subject in need thereof, comprising administering to the subject the composition of claim 2 .

7. The method of claim 6 , wherein the subject has excessive daytime sleepiness.

Assignments (2)
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
SECURITY INTEREST Recorded Sep 9, 2024
From: AXSOME MALTA LTD
To: HERCULES CAPITAL, INC.
Reel/Frame 068900/0023 →
Continuity (4)
Continuation 17091222 · Nov 6, 2020
Continuation 16331069
Provisional Application 62383822 · Sep 6, 2016
Related Publication 20230183172A1 · Jun 15, 2023
References Cited (58)
US 5955499A · Choi et al. · 1999 [cited by applicant]
US 6350596B2 · Iomantas et al. · 2002 [cited by applicant]
US 9403761B2 · Kang et al. · 2016 [cited by applicant]
US 9604917B2 · Ahnaou et al. · 2017 [cited by applicant]
US 9649291B2 · Khayrallah et al. · 2017 [cited by applicant]
US 10829443B2 · Nelson et al. · 2020 [cited by applicant]
US 20050080268A1 · Choi et al. · 2005 [cited by applicant]
US 20100331332A1 · Lee et al. · 2010 [cited by applicant]
US 20140350098A1 · Ahnaou et al. · 2014 [cited by applicant]
US 20150025136A1 · Khayrallah et al. · 2015 [cited by applicant]
US 20150246874A1 · Kang et al. · 2015 [cited by applicant]
US 20160081970A1 · Khayrallah et al. · 2016 [cited by applicant]
US 20220162159A1 · Bhirud · 2022 [cited by examiner]
CN 1135209A · 1996 [cited by applicant]
JP H09503231A · 1997 [cited by applicant]
JP 2007508293A · 2007 [cited by applicant]
JP 2008546778A · 2008 [cited by applicant]
JP 2016532679A · 2016 [cited by applicant]
JP 2017512211A · 2017 [cited by applicant]
JP 2019512009A · 2019 [cited by applicant]
KR 100197892B1 · 1999 [cited by applicant]
KR 20080035565A · 2008 [cited by applicant]
KR 20160032127A · 2016 [cited by applicant]
WO 9607637A1 · 1996 [cited by applicant]
WO 2005033064A1 · 2005 [cited by applicant]
WO 2007001841A1 · 2007 [cited by applicant]
WO 2017140778A1 · 2017 [cited by applicant]
“Office Action corresponding to Philippine Application No. 1-2019-5000493 issued Feb. 13, 2023”. [cited by applicant]
“Written Opinion corresponding to Singapore Application No. 11201901998W dated May 16, 2022”. [cited by applicant]
“Examination Report corresponding to European Application No. 17849432.4 dated May 11, 2021”. [cited by applicant]
“Extended European Search Report corresponding to European Application No. 17849432.4 dated Apr. 9, 2020”. [cited by applicant]
“International Preliminary Report on Patentability corresponding to International Application No. PCT/US2017/050233 mailed Mar. 21, 2019”. [cited by applicant]
“International Search Report and Written Opinion corresponding to International Application No. PCT/US2017/050233 mailed Nov. 13, 2017”. [cited by applicant]
“International Search Report corresponding to Singapore Application No. 11201901998W dated May 2, 2020”. [cited by applicant]
“Office Action corresponding to Chinese Application No. 201780065192.6 issued Dec. 6, 2021”. [cited by applicant]
“Office Action corresponding to Chinese Application No. 2017800651926 issued Jul. 5, 2021”. [cited by applicant]
“Office Action corresponding to Chinese Application No. 2017800651926 issued Mar. 9, 2022”. [cited by applicant]
“Office Action corresponding to European Application No. 17849432.4 dated Apr. 8, 2022”. [cited by applicant]
“Office Action corresponding to Indian Application No. 201917009658 mailed Nov. 24, 2020”. [cited by applicant]
“Office Action corresponding to Indonesian Application No. PID201902732 dated Dec. 6, 2021”. [cited by applicant]
“Office Action corresponding to Indonesian Application No. PID201902732 dated Jul. 27, 2021”. [cited by applicant]
“Office Action corresponding to Indonesian Application No. PID201902732 Mar. 18, 2021”. [cited by applicant]
“Office Action corresponding to Japanese Application No. 2019-512895 mailed Dec. 12, 2021”. [cited by applicant]
“Office Action corresponding to Japanese Application No. 2019-512895 mailed Jun. 27, 2022”. [cited by applicant]
“Office Action corresponding to Japanese Application No. 2019-512895 mailed Jun. 28, 2021”. [cited by applicant]
“Office Action corresponding to Korean Application No. 10-2019-7011279 issued Jul. 20, 2022”. [cited by applicant]
“Office Action corresponding to Philippine Application No. 1-2019-500493 mailed Feb. 10, 2022”. [cited by applicant]
“Phenprobamate, Wikipedia, https://en.wikipedia.org/wiki/Phenprobamate, last edited Apr. 2, 2016, accessed Sep. 24, 2019”. [cited by applicant]
“Written Opinion corresponding to Singapore Application No. 11201901998W dated Jun. 29, 2021”. [cited by applicant]
“Written Opinion corresponding to Singapore Application No. 11201901998W dated May 6, 2020”. [cited by applicant]
Ashizawa, Kazuhide , et al., “Science of Polymorphism and crystallization of the pharmaceutical drugs: Trends in development, manufacturing and regulations”, Sep. 20, 2002, 273-278. [cited by applicant]
Fang, Lao , et al., “Inventiveness of Crystal Forms of a Drug, from the view of Patent Invalidation or Administrative Litigation Cases”, China Invention & Patent 2:110-116 (Feb. 16, 2016). [cited by applicant]
“Office Action corresponding to Philippine Application No. 1-2019-500493 mailed Nov. 28, 2023”. [cited by applicant]
“Office Action corresponding to Indonesian Application No. PID201902732 issued Mar. 10, 2023”. [cited by applicant]
“Office Action corresponding to Japanese Application No. 2021-155292 mailed Jul. 20, 2023”. [cited by applicant]
“Office Action corresponding to European Application No. 17849432.4 dated Dec. 9, 2022”. [cited by applicant]
“Office Action corresponding to Malaysian Application No. PI2019001180 issued Jan. 31, 2023”. [cited by applicant]
“Third Party Observations corresponding to European Application No. 17849432.4 dated Feb. 15, 2023”. [cited by applicant]